Galeterone

Galeterone

Galeterone
Systematic (IUPAC) name
17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol
Clinical data
Legal status
?
Routes Oral
Identifiers
CAS number
ATC code ?
PubChem
ChemSpider
KEGG  YesY
Chemical data
Formula C26H32N2O 
Mol. mass 388.25

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of the androgens.[1] As of the second half of 2014, galeterone is in phase III clinical trials for castration-resistant prostate cancer.[2]

See also

References

  1. ^ Brawer MK (2008). "New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chicago, IL". Rev Urol 10 (4): 294–6.  
  2. ^ Yahoo! Finance (2014). "Tokai Pharmaceuticals’ Reformulated Galeterone Demonstrates Robust PSA Reductions in Advanced Prostate Cancer Patients".